In recent months, a heated debate has emerged about the credibility of major medical journals such as the New England Journal of Medicine, the Journal of the American Medical Association, and The Lancet. Critics, including United States Health and Human Services Secretary Robert F. Kennedy Junior, have argued that these journals are compromised by pharmaceutical industry influence and therefore cannot be trusted. At first glance, the claim may sound extreme. But the reason it resonates with some people is that it touches on a real issue: the complex and sometimes uncomfortable relationship between biomedical research and industry funding. The problem, however, is not as simple as declaring journals corrupt or trustworthy. The real question is much more nuanced: How do we evaluate scientific evidence in a system that is both imperfect and continually evolving?
The uncomfortable truth about industry influence
Pharmaceutical companies fund a large portion of clinical research. Clinical trials are expensive, and industry funding has become a central part of the biomedical research ecosystem. Numerous analyses have shown that industry-funded studies are more likely to produce results favorable to the sponsor’s product. That does not necessarily mean the research is fraudulent, but it highlights structural pressures that can influence study design, data interpretation, and publication decisions. These concerns are not new. In fact, some of the most pointed critiques have come from within the medical establishment itself. Former New England Journal of Medicine editor Marcia Angell famously argued that financial conflicts of interest had become so pervasive that they threatened confidence in the clinical research literature. Similarly, philosopher Sergio Sismondo has documented how pharmaceutical companies sometimes use strategies known as “publication planning,” in which contract research organizations, medical writers, statisticians, and academic authors collaborate to produce research papers aligned with marketing goals. These critiques deserve to be taken seriously. But acknowledging these problems does not mean that the entire scientific publishing system is irredeemably corrupt.
Science has been reforming itself for decades
The important part of this story is often overlooked: The scientific publishing system has spent decades trying to address these weaknesses. Medical journals now require extensive conflict of interest disclosures from authors. Researchers must report financial relationships with companies related to their work so readers can interpret findings with appropriate context. Another reform has been clinical trial registration. Many trials must now be registered in public databases before they begin. This requirement helps prevent selective reporting, where only positive outcomes are published while negative findings remain hidden. Editorial organizations such as the International Committee of Medical Journal Editors have also established detailed standards governing authorship, transparency, and data access. These measures do not eliminate bias, but they demonstrate something important: The scientific community has recognized the problem and has been actively trying to improve the system.
Peer review is essential, but not infallible
Peer review remains the central mechanism used to evaluate research before publication. Independent experts examine submitted manuscripts, assessing methodology, statistical analysis, and interpretation of results. Yet peer review is not a guarantee of truth. Reviewers can miss errors. Fraudulent research occasionally slips through. Some papers that initially appear groundbreaking are later challenged or overturned. Recognizing these limitations, some journals have begun experimenting with more transparent peer review models, publishing reviewer comments alongside accepted articles. In some cases, reviewers may choose to reveal their identities. These changes reflect an evolving recognition that transparency can strengthen trust in the scientific process.
The rise of preprints complicates the landscape
Another major shift in scientific communication has been the rapid growth of preprint servers for biology and medicine. These platforms allow researchers to post manuscripts online before they undergo formal peer review. Preprints can accelerate scientific collaboration and allow new ideas to be discussed earlier. But they also create new challenges. During the coronavirus disease 2019 pandemic, preprints were frequently reported in the media as if they were definitive studies. In reality, preprints are preliminary research that has not yet undergone rigorous review. For clinicians and the public alike, this raises a critical issue: Not all “studies” carry the same weight of evidence.
Why systematic evidence matters
This is where systematic reviews and evidence syntheses become especially valuable. Organizations like Cochrane analyze the full body of available research on a given topic using standardized methods designed to minimize bias. By examining multiple studies collectively, systematic reviews provide a more reliable picture of the evidence than any single paper can. In medicine, strong conclusions rarely come from a single study. They emerge from the accumulation of evidence over time.
The real danger of abandoning the system entirely
Critics who claim that major journals are irreparably corrupt often propose radical alternatives, such as replacing existing journals with government run publishing platforms or dismissing mainstream medical research altogether. But abandoning the current system would likely create new problems rather than solving old ones. If independent journals are weakened or replaced by politically aligned outlets, editorial independence could be compromised. If public funding for research declines, scientists may become even more dependent on private industry funding, the very conflict critics seek to eliminate. The solution to flaws in the scientific system is not to dismantle the system itself, but to continue strengthening its safeguards.
Rebuilding trust in science
Public trust in science has been strained in recent years, particularly following the coronavirus disease 2019 pandemic. Conflicting studies, changing recommendations, and the rapid spread of misinformation have made it harder for many people to know whom to trust. Rebuilding that trust requires honesty about the system’s limitations. Scientific research is conducted by human beings, within institutions shaped by economic and political pressures. Errors occur. Bias can exist. But science also has a remarkable capacity for self-correction. Findings are challenged. Methods improve. Weak evidence is eventually replaced by stronger evidence. That process can be messy and slow, but it remains one of the most reliable ways humanity has developed knowledge.
Science is not an authority, it is a process
In the end, the credibility of medical research should not depend on trust in a single institution, journal, or expert. It should depend on the weight of transparent, reproducible evidence evaluated over time. Medical journals, peer review, systematic evidence synthesis, and research transparency are all parts of that system. Criticism of these institutions is healthy when it pushes them to improve. But dismissing them entirely risks undermining the very framework that allows science to correct itself. The goal should not be to replace one flawed authority with another. The goal should be to strengthen the process that allows evidence, not ideology, to guide medical decisions.
Laurel A. Coons is a scientist with a background in genomics and biomedical research. She completed her doctoral training in pharmacology and cancer biology at Duke University and conducted research at the National Institute of Environmental Health Sciences. Her work has focused on genomic regulation, endocrine signaling, and translating complex scientific data into insights relevant to medicine and patient care.
She shares professional updates on X at laurelcoons.
